SEARCH

SEARCH BY CITATION

References

  • 1
    Lai CL, Ratziu V, Yuen MF, Poynard T. Viral Hepatitis. Lancet 2003; 3: 208994.
  • 2
    Ganem D, Prince M. Hepatitis B virus infection. Natural history and clinical consequences. N Engl J Med 2004; 350: 111829.
  • 3
    Estimation des taux de prévalence des anticorps anti-VHC et des marqueurs de l’hépatite B chez les assurés sociaux du régime général de France métropolitaine, 2003–2004. Analyse descriptive, InVS, janvier 2005. http://www.invs.sante.fr/publication/2005.
  • 4
    Manesis EK. HBeAg-negative chronic hepatitis B: from obscurity to prominence. J Hepatol 2006; 45: 34345.
  • 5
    Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe-positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 26370.
  • 6
    Hadziyannis SJ, Vassilopoulos D. Hepatitis Be antigen-negative chronic hepatitis B. Hepatology 2001; 34: 61724.
  • 7
    Lampertico P, Del Ninno E, Manzin A, et al. A randomized controlled trial of a 24-month course of interferon alpha2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 162125.
  • 8
    Papatheodoridis GV, Manesis E, Hadziyannis JJ. The long-term outcome of interferon-treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 30613.
  • 9
    Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 76368.
  • 10
    Yoo BC, Park JW, Kim HJ, Lee DH, Cha YJ, Park SM. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. J Hepatol 2003; 38: 98103.
  • 11
    Zarski JP, Marcellin P, Cohard M, et al. Comparison of anti-HBe-positive and HBeAg-positive chronic hepatitis B in France. J Hepatol 1994; 20: 63640.
  • 12
    Zarski JP, Marcellin P, Leroy V, et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBeAg-negative cases. J Hepatol 2006; 45: 35560.
  • 13
    Lahmek P, Cadranel JF, Si Ahmed SN, Eugène C, Fontanges T, Lesgourgues B et al. Chronic hepatitis B treatment outside therapeutic protocols results of a French descriptive study. Gastroenterology 2003; 124: J (abstract)
  • 14
    Saldanha J, Gerlich W, Lelie N, et al. An international collaborative study to establish a world health organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001; 80: 6371.
  • 15
    Bedossa P, Poynard T. An algorytm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 28993.
  • 16
    Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 43135.
  • 17
    Bruix J, Sherman M, Lovet JM, et al. Panel expert on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver J Hepatol 2001; 35: 42130.
  • 18
    Hanley J, Mc Neil B. The meaning and use of the area under the receiver operating characteristic (ROC) curve. Radiology 1982; 143: 2936.
  • 19
    Hanley J, Mc Neil B. A method of comparing the areas under receiver operating curves derived from the same cases. Radiology 1983; 148: 83943.
  • 20
    Marcellin P. Histoire naturelle de l’hépatite virale B. In: TrepoC, VallaD, eds. Progrès en hépatologie Hepatites Virales. Paris: Doin. 1993; 3349.
  • 21
    Mangia A, Chung YH, Hoofnagle JH, Birken-Meyer L, Mushahwar I, Di Bisceglie AM. Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. Dig Dis Sci 1996; 41: 244752.
  • 22
    Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine precore mutant group. Hepatology 1999; 29: 88996.
  • 23
    Chu CJ, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38: 61928.
  • 24
    Knoll A, Rohihofer A, Kocharowski B, Wurm Em, Jily W. Prevalence of precore mutation in anti-HBe-positive hepatitis B virus carrier in Germany. J Med Virol 1999; 59: 1418.
  • 25
    Ganne-Carrié N, Williams V, Kaddouri H, et al. Significance of hepatitis B virus genotypes. A to E in a cohort of patients with chronic hepatitis B in the Seine Saint Denis, district of Paris (France). J Med Virol 2006; 78: 33540.
  • 26
    Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 197080.
    Direct Link:
  • 27
    Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during differents stages of chronic hepatitis B infection. Hepatology 2002; 36: 140815.
  • 28
    Mommega-Marin H, Mondon E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 130919.
  • 29
    De Franchis R, Hadengue A, Lau G, et al. International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39(Suppl 1): S125.
  • 30
    Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 2733.
  • 31
    Mathurin P, Thibault V, Kadidja K, et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepatitis 2000; 7: 1522.
  • 32
    Di Martino V, Thévenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123: 181222.
  • 33
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B: summary of a workshop. Gastroenterology 2001; 120: 182853.
  • 34
    Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors of chronic hepatitis type B. Gut 1991; 32: 29498.
  • 35
    Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988; 8: 165154.
  • 36
    McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24(Suppl. 1): 1721.
  • 37
    Xu B, Hu DC, Rosenberg DM, et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol 2003; 18: 134552.
  • 38
    Wu GC, Zhou WP, Zhao YR, et al. The natural history of chronic hepatitis B: a retrospective study. Hepatobiliary Pancreat Dis Int 2003; 2: 56670.
  • 39
    Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002; 186: 295301.
  • 40
    Deuffic-Burban S, Poynard T, Valleron AJ. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepatol 2002; 9: 11422.
  • 41
    Myers RP, Tainturier MH, Ratziu V, Piton I, Thibault V, Imbert-Bismut F. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 29: 22230.
  • 42
    Hui AY, Chan HL, Wong VW, et al. Identification of chronic Hepatitis B patients without significant liver fibrosis by a simple non-invasive predictive model. Am J Gastroenterol 2005; 100: 61623.
    Direct Link:
  • 43
    Wai CT, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 51826.
  • 44
    Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 137381.
  • 45
    Wai CT, Chang CL, We A, Dan YY, Chan E, Chua N. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006; 26: 66672.
  • 46
    Croquet V, Vuillemin E, Ternisien C, et al. Prothrombin Index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 2002; 14: 113341.
  • 47
    Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 85761.